AAAAAA

   
Results: 1-23 |
Results: 23
Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ
Authors: Bluman, LG Borstelmann, NA Rimer, BK Iglehart, JD Winer, EP
Citation: Lg. Bluman et al., Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ, J WOMEN H G, 10(6), 2001, pp. 589-598
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy
Authors: Demark-Wahnefried, W Peterson, BL Winer, EP Marks, L Aziz, N Marcom, PK Blackwell, K Rimer, BK
Citation: W. Demark-wahnefried et al., Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy, J CL ONCOL, 19(9), 2001, pp. 2381-2389
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
Authors: Burstein, HJ Kuter, I Campos, SM Gelman, RS Tribou, L Parker, LM Manola, J Younger, J Matulonis, U Bunnell, CA Partridge, AH Richardson, PG Clarke, K Shulman, LN Winer, EP
Citation: Hj. Burstein et al., Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer, J CL ONCOL, 19(10), 2001, pp. 2722-2730
Liposomal anthracyclines for breast cancer
Authors: Sparano, JA Winer, EP
Citation: Ja. Sparano et Ep. Winer, Liposomal anthracyclines for breast cancer, SEMIN ONCOL, 28(4), 2001, pp. 32-40
New cytotoxic agents and schedules for advanced breast cancer
Authors: Burstein, HJ Bunnell, CA Winer, EP
Citation: Hj. Burstein et al., New cytotoxic agents and schedules for advanced breast cancer, SEMIN ONCOL, 28(4), 2001, pp. 344-358
New combinations with Herceptin((R)) in metastatic breast cancer
Authors: Winer, EP Burstein, HJ
Citation: Ep. Winer et Hj. Burstein, New combinations with Herceptin((R)) in metastatic breast cancer, ONCOL-BASEL, 61, 2001, pp. 50-57
Survivors of breast cancer - Reply
Authors: Burstein, HJ Winer, EP
Citation: Hj. Burstein et Ep. Winer, Survivors of breast cancer - Reply, N ENG J MED, 344(4), 2001, pp. 309-310
NCCN Practice Guidelines for breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, CE Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS McCormick, B Nabell, LM Reed, EC Silver, SM Smith, ML Somlo, G Theriault, R Ward, JH Winer, EP Wolff, A
Citation: Rw. Carlson et al., NCCN Practice Guidelines for breast cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 33-49
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique - In Reply
Authors: Hensley, ML Schuchter, LM Winer, EP Meropol, NJ Pfister, D
Citation: Ml. Hensley et al., Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique - In Reply, J CL ONCOL, 18(9), 2000, pp. 2005-2006
Docetaxel administered on a weekly basis for metastatic breast cancer
Authors: Burstein, HJ Manola, J Younger, J Parker, LM Bunnell, CA Scheib, R Matulonis, UA Garber, JE Clarke, KD Shulman, LN Winer, EP
Citation: Hj. Burstein et al., Docetaxel administered on a weekly basis for metastatic breast cancer, J CL ONCOL, 18(6), 2000, pp. 1212-1219
Phase II evaluation of thalidomide in patients with metastatic breast cancer
Authors: Baidas, SM Winer, EP Fleming, GF Harris, L Pluda, JM Crawford, JG Yamauchi, H Isaacs, C Hanfelt, J Tefft, M Flockhart, D Johnson, MD Hawkins, MJ Lippman, ME Hayes, DF
Citation: Sm. Baidas et al., Phase II evaluation of thalidomide in patients with metastatic breast cancer, J CL ONCOL, 18(14), 2000, pp. 2710-2717
Primary care - Primary care for survivors of breast cancer
Authors: Burstein, HJ Winer, EP
Citation: Hj. Burstein et Ep. Winer, Primary care - Primary care for survivors of breast cancer, N ENG J MED, 343(15), 2000, pp. 1086-1094
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181
Authors: Dawson, NA Conaway, M Halabi, S Winer, EP Small, EJ Lake, D Vogelzang, NJ
Citation: Na. Dawson et al., A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181, CANCER, 88(4), 2000, pp. 825-834
Testing for hereditary breast and ovarian cancer in the southeastern United States
Authors: Miron, A Schildkraut, JM Rimer, BK Winer, EP Skinner, CS Futreal, PA Culler, D Calingaert, B Clark, S Marcom, PK Iglehart, JD
Citation: A. Miron et al., Testing for hereditary breast and ovarian cancer in the southeastern United States, ANN SURG, 231(5), 2000, pp. 624-632
Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support
Authors: Winer, EP Lindley, C Hardee, M Sawyer, WT Brunatti, C Borstelmann, NA Peters, W
Citation: Ep. Winer et al., Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support, PSYCHO-ONC, 8(2), 1999, pp. 167-176
Phase I study of Doxil and vinorelbine in metastatic breast cancer
Authors: Burstein, HJ Ramirez, MJ Petros, WP Clarke, KD Warmuth, MA Marcom, PK Matulonis, UA Parker, LM Harris, LN Winer, EP
Citation: Hj. Burstein et al., Phase I study of Doxil and vinorelbine in metastatic breast cancer, ANN ONCOL, 10(9), 1999, pp. 1113-1116
Update: NCCN practice guidelines for the treatment of breast cancer
Authors: Carlson, RW Anderson, BO Bensinger, W Cox, C Davidson, NE Edge, SB Farrar, WB Goldstein, LJ Gradishar, WJ Lichter, AS Mccormick, B Nabell, LM Reed, EC Silver, SM Smith, MLP Somlo, G Theriault, RL Winer, EP
Citation: Rw. Carlson et al., Update: NCCN practice guidelines for the treatment of breast cancer, ONCOLOGY-NY, 13(11A), 1999, pp. 187-212
Hydrocortisone with or without mitoxantrone in men with hormone-refractoryprostate cancer: Results of the Cancer and Leukemia Group B 9182 study
Authors: Kantoff, PW Halabi, S Conaway, M Picus, J Kirshner, J Hars, V Trump, D Winer, EP Vogelzang, NJ
Citation: Pw. Kantoff et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractoryprostate cancer: Results of the Cancer and Leukemia Group B 9182 study, J CL ONCOL, 17(8), 1999, pp. 2506-2513
Is axillary lymph node dissection indicated for early-stage breast cancer?A decision analysis
Authors: Parmigiani, G Berry, DA Winer, EP Tebaldi, C Iglehart, JD Prosnitz, LR
Citation: G. Parmigiani et al., Is axillary lymph node dissection indicated for early-stage breast cancer?A decision analysis, J CL ONCOL, 17(5), 1999, pp. 1465-1473
Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2
Authors: Bluman, LG Rimer, BK Berry, DA Borstelmann, N Iglehart, JD Regan, K Schildkraut, J Winer, EP
Citation: Lg. Bluman et al., Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2, J CL ONCOL, 17(3), 1999, pp. 1040-1046
American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants
Authors: Hensley, ML Schuchter, LM Lindley, C Meropol, NJ Cohen, GI Broder, G Gradishar, WJ Green, DM Langdon, RJ Mitchell, B Negrin, R Szatrowski, TP Thigpen, JT Von Hoff, D Wasserman, TH Winer, EP Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
Authors: Goss, PE Winer, EP Tannock, IF Schwartz, LH
Citation: Pe. Goss et al., Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients, J CL ONCOL, 17(1), 1999, pp. 52-63
Inability to escalate vinorelbine dose intensity using a daily x3 schedulewith and without filgrastim in patients with metastatic breast cancer
Authors: Havlin, KA Ramirez, MJ Legler, CM Harris, LN Matulonis, UA Hohneker, JA Hayes, DF Winer, EP
Citation: Ka. Havlin et al., Inability to escalate vinorelbine dose intensity using a daily x3 schedulewith and without filgrastim in patients with metastatic breast cancer, CANC CHEMOT, 43(1), 1999, pp. 68-72
Risultati: 1-23 |